The Holy Grail of oncology is personalized cancer therapy. While
patients with either malignant ovarian germ cell tumors or ovarian sex
cord-stromal tumors, constituting two of the three major categories of
ovarian cancer, have historically been treated on separate clinical
trials, women with all types of epithelial tumors have been treated
identically on the same trials over the past several decades.